(11) 98705-3426
TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

TRINOMAB

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: MistaEscritório: US

Snapshot rápido

TRINOMAB

ST13

US500000079350028

Classe

35, 42, 44

Pedido

79350028

Registro

7470062

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

44

Atualização mais recente

26/12/2025

Classificação

Registrada

Tipo de marca

Mista

Classes Nice

35, 42, 44

Data de depósito

12/07/2022

Data de registro

13/08/2024

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

13/08/2024

Última transação

26/12/2025

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

3

Tipo de titular

99

Localização do titular

CN

Examinador

FLETCHER,TRACY L

Unidade examinadora

M60

Localização atual

FILE REPOSITORY (FRANCONIA)

Titulares e representantes

Titulares

Zhuhai Trinomab Pharmaceutical Co., Ltd.

Representantes

Scot A. Duvall STITES & HARBISON PLLC

Classificação técnica

Classes Nice

Classe 35Classe 42Classe 44

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 35

Retail store services and wholesale distributorship services featuring veterinary pharmaceutical preparations; retail store services featuring pharmaceuticalveterinary and sanitary preparations and medical supplies; wholesale distributorship services featuring pharmaceuticalveterinary and sanitary preparations and medical supplies; wholesale store services featuring pharmaceuticalveterinary and sanitary preparations and medical supplies; retail store services and wholesale distributorship services featuring pharmaceutical preparations; retail and wholesale store services featuring pharmaceutical preparations; all of the foregoing featuring monoclonal antibodiesnone of the above related to the treatment or prevention of cardiovascular diseases

Classe 42

Scientific research; technological research in the field of pharmaceuticals; technological research in the fields of geneticsgenetic engineeringmolecular biology and cellular immunology; conducting technical project studiesconducting scientific feasibility studies; scientific laboratory services; research and development of new products for others; chemical analysis; chemical research; biological research; scientific research in the nature of conducting clinical trials for others; chemistry services in the nature of chemist services; chemistry servicesconsultationresearch and advice; none of the above related to the treatment or prevention of cardiovascular diseases

Classe 44

Hospital services; medical assistance; nursingmedical; medicalphysical rehabilitation and physical therapy services; alternative medicine services; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; DNA screening for medical purposes; medical analysis services for the diagnosis of cancer; blood collection servicescollection and preservation of human blood; performing diagnosis of diseases; collection and preservation of human blood; genetic testing for medical purposes; behavioral analysis for medical purposes; rental of medical instruments and apparatus; stem cell therapy services; veterinary assistance; all of the foregoing featuring monoclonal antibodiesnone of the above related to the treatment or prevention of cardiovascular diseases

Publicações

Histórico de despachos e eventos da marca no USPTO.

44 publicações encontradas

EWAF

TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS

24/12/2025

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

24/12/2025

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

24/12/2025

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

24/12/2025

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

24/12/2025

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

29/03/2025

XXSS

GENERIC MADRID TRANSACTION SENT TO IB

01/02/2025

XXCR

GENERIC MADRID TRANSACTION CREATED

01/02/2025

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

13/11/2024

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

13/08/2024

R.PR

REGISTERED-PRINCIPAL REGISTER

13/08/2024

GPNX

NOTIFICATION PROCESSED BY IB

11/06/2024

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

28/05/2024

PUBO

PUBLISHED FOR OPPOSITION

28/05/2024

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

15/05/2024

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

15/05/2024

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

08/05/2024

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

24/04/2024

XAEC

EXAMINER'S AMENDMENT ENTERED

24/04/2024

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

24/04/2024

GNEA

EXAMINERS AMENDMENT E-MAILED

24/04/2024

CNEA

EXAMINERS AMENDMENT -WRITTEN

24/04/2024

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

11/03/2024

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

21/02/2024

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

21/02/2024

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

11/10/2023

GNFR

FINAL REFUSAL E-MAILED

11/10/2023

CNFR

FINAL REFUSAL WRITTEN

11/10/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

02/10/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

30/09/2023

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

30/09/2023

ADCH

CHANGE OF NAME/ADDRESS REC'D FROM IB

22/09/2023

RFNT

REFUSAL PROCESSED BY IB

22/07/2023

ATRV

ATTORNEY REVIEW COMPLETED

30/06/2023

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

28/06/2023

RFRR

REFUSAL PROCESSED BY MPU

28/06/2023

LIME

LIMITATION FROM THE IB - REQUEST EXAM REVIEW

27/06/2023

LIMG

LIMITATION OF GOODS RECEIVED FROM IB

10/06/2023

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

29/04/2023

CNRT

NON-FINAL ACTION WRITTEN

28/04/2023

DOCK

ASSIGNED TO EXAMINER

26/04/2023

MAFR

APPLICATION FILING RECEIPT MAILED

23/09/2022

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

19/09/2022

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

16/09/2022

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace TRINOMAB ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.